US › Healthcare

Larimar Therapeutics Inc (LRMR)

US · Healthcare · Biotechnology

$3.80-3.31%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-32.8M

EPS

$-0.30

EPS estimate

$-0.39

EPS came in at -0.30 against a street estimate of -0.39 — a beat of 23.1%.

Key statistics

Market cap

$399.9M

Forward P/E

0.0

P/B

3.16

Book value

$1.22

EPS (TTM)

$-2.00

52-week high

$6.42

52-week low

$2.71

50-day MA

$3.92

200-day MA

$3.94

Beta

0.75

Analyst view

Analysts rate Larimar Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $14.30.

Shareholding

Insiders

1.15%

Institutions

93.38%

Largest institutional holders

Fund	Stake
Deerfield Management Co	34.28%
Blue Owl Capital Holdings LP	8.82%
BlackRock Inc	3.61%
Defilade Capital Management, L.P.	3.53%
Driehaus Capital Management LLC	2.82%
Vanguard Capital Management, LLC	2.76%
Dafna Capital Management LLC	1.95%
The Goldman Sachs Group Inc	1.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Larimar Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.